Genetic disorders and mortality in infancy and early childhood: delayed diagnoses and missed opportunities

Monica H. Wojcik, MD1,2,3, Talia S. Schwartz, BA2,3, Inbar Yamin, BSc2,3, Heather L. Edward, BA2,3, Casie A. Genetti, MS2,3, Meghan C. Towne, MS2,3,4 and Pankaj B. Agrawal, MD, MMSc1,2,3

INTRODUCTION

Infants admitted to a level IV neonatal intensive-care unit (NICU) often have rare genetic disorders; these infants contribute considerably to mortality figures both in the NICU1–5 and in early childhood.6,7 The term “genetic disorders” is broad and in this context refers to chromosomal abnormalities, such as aneuploidy syndromes or chromosomal deletion or duplication disorders, in addition to Mendelian disorders, such as inborn errors of metabolism, which also contribute to NICU admissions and mortality.8 Additionally, congenital malformations, affecting approximately 2% of live births,9 are responsible for a large proportion of NICU admissions3,4 and are the leading cause of infant mortality in the United States,1 although the underlying etiology of these malformations may not be genetic, as seen in diabetic embryopathy or in utero exposure to known teratogens such as phenytoin. Regardless, infants with genetic disorders and congenital malformations indicating a possible genetic syndrome not only comprise a substantial proportion of NICU admissions, but also disproportionately contribute to neonatal mortality, representing 30–50% of neonatal and infant deaths.1,3,4,11,12

Infants admitted to the NICU who do not survive early childhood are therefore a population that is probably enriched for genetic disease. The process of arriving at a genetic diagnosis has been termed the “diagnostic odyssey.” The traditional diagnostic genetic evaluation has previously been shown to have a yield of approximately 46%, and it took an average of 7–8 months for children and adults evaluated in an outpatient genetics clinic. However, for laboratory-confirmed (molecular) genetic diagnoses, this yield dropped to 27%.13 Rapid whole-genome sequencing (WGS) in critically ill newborns and infants has been demonstrated to have a diagnostic yield as high as 50%–70%.14–17 in a research setting, and a recent retrospective analysis found a diagnostic yield of 36.7% using clinical whole-exome sequencing (WES).18 There is a paucity of information regarding the traditional genetic diagnostic evaluation in the NICU, with one previous study showing a diagnostic yield of 26% for infants who had their initial genetic consultation while in the NICU, although most were diagnosed after NICU discharge.19 However, NICU infants, particularly nonsurvivors, could benefit immensely from an expeditious genetic diagnosis. It has been shown that finding a genetic diagnosis can aid in the clinical management of critically ill infants or can lead to the decision to redirect care in the setting of a poor prognosis.16,19 which is of particular importance in the NICU as previous studies have shown that the majority of deaths occur under these circumstances.1,3,20 We therefore investigated how many of these NICU infants who died before 5 years of age had
a genetic diagnosis made and analyzed the genetic diagnostic evaluation in this population.

**MATERIALS AND METHODS**

**Study population**

This is a retrospective analysis of the electronic medical records of patients first admitted to the level IV NICU at our institution between 1 January 2011 and 31 December 2015 who were deceased at the time of records review with an age at death of under 5 years. The Boston Children’s Hospital Institutional Review Board approved this study with a waiver of informed consent due to the nature of the study.

Deceased patients were identified by reviewing the list of admissions from this time period and including patients whose status in our electronic medical record was recorded as “deceased” as of 28 November 2017 and whose age at the time of death was less than 5 years. All deaths occurring within our institution would be captured by this method, as would deaths occurring outside our institution, provided the information is returned so that the medical record can be updated accordingly.

**Data collection and analysis**

Study data were collected and managed using REDCap (Research Electronic Data Capture) hosted at Boston Children’s Hospital. For further details, please see the Supplementary Methods online.

For each patient, we recorded whether or not a genetics or metabolism consultation was obtained at our institution. If yes, information on the date, location, and indication for consultation was obtained. We reviewed all genetic testing results and recorded the type of genetic test in addition to the result, the date the specimen was received by the lab, and the date of the report containing the results. We did include tests sent prior to transfer to our institution using the information available in our electronic medical record. Gene tests that were ordered as a panel but for which results for each gene were provided separately were entered as individual gene tests as the turnaround time may vary by gene. We determined whether a laboratory-confirmed molecular or cytogenetic diagnosis was made based on these test results. Patients were considered to have a laboratory-confirmed genetic diagnosis if they had a pathogenic or likely pathogenic variant found on a genetic test that explained the patient’s presentation. For cases in which two variants were found in a single gene associated with an autosomal recessive disorder, but parental testing was not available to determine whether the variants were in cis or trans, or if one of the two variants was a variant of uncertain significance (VUS) present in combination with a pathogenic or likely pathogenic variant, these variants were also considered to be disease-causing if the phenotype matched appropriately. If the diagnostic status was unclear from the test report alone, the medical notes were reviewed to find the opinion of the treating physician. For patients with laboratory-confirmed genetic diagnoses, we reviewed the clinical notes preceding the date of this diagnosis to determine whether a clinical diagnosis had been made prior to the molecular or cytogenetic result; patients were determined to have a clinical diagnosis if the provider had documented that the patient had a specific condition. A clinical diagnosis was not considered made if the provider documented being highly suspicious for a particular disorder but other conditions were also on the differential or if testing for other conditions was being sent concurrently.

Statistical analysis was performed using SPSS (version 23.0, IBM, Armonk, NY), using descriptive and chi-square analyses and the Mann-Whitney U-test and a two-sided Fisher’s exact test to compare variables when appropriate.

**RESULTS**

**Characteristics of the study population**

Over the 5-year period, 2,670 infants were admitted to the NICU and 170 of them later died. Of the 170 who died, 102 (60%) were male and 68 (40%) were female; 149 (88%) died before 1 year of age. Additional characteristics of these infants are provided in Table 1, and causes of death are displayed in Figure 1. Death occurred after redirection of the goals of care for 137/164 infants (84%), and life support was withdrawn for 116/153 infants (76%) for whom data were available. Autopsy was performed, with results available in our records, for 61/170 infants (36%). For the infants who later died, after the initial admission, 93 infants (55%) died in the NICU, 12 (7%) were discharged home, 48 (28%) were transferred to another unit of the hospital, and 17 (10%) were transferred to another hospital for further care.

**Evaluation for a genetic or metabolic disorder**

The genetics or metabolism service was consulted for 87 (51%) of the 170 patients who died, with multiple congenital anomalies being the most common indication for consultation (46/87, 53%), followed by a suspected metabolic disorder (18/87, 21%), known genetic syndrome (10/87, 12%), neurologic disorder (5/87, 6%), single congenital malformation (4/87, 5%), hematologic/oncologic disorder (2/87, 2%), and pulmonary hypertension (2/87, 2%). The median age at first genetics or metabolism consultation (by our institution) was 10.0 days (25th–75th percentile (Q1–Q3) 3.0–40.0, range 0.0–783.0 days), and 72/87 (83%) had this consultation performed before or on the day of the first NICU discharge. All but four patients had the initial consultation at our hospital while inpatients and two of the four who had the initial consultation performed in an outpatient clinic visit subsequently had inpatient consultations at our institution. In contrast, 634/2,670 infants admitted to the NICU (24%) overall had a genetics or metabolism consultation or clinic visit in their first 5 years of life.

At least one postnatal test for a genetic or metabolic condition was performed for 96/170 (57%) of these patients, including cytogenetic and molecular genetic tests (Table 2) in addition to biochemical testing for a metabolic condition, enzyme analysis, and tissue biopsies. Three had testing for somatic variants causing malignancy. Six patients underwent
only biochemical testing for a metabolic condition (e.g., plasma amino acids, urine organic acids), and one had only a biopsy performed for a genetic condition (junctional epidermolysis bullosa). The 87 patients who had cytogenetic or molecular genetic testing (Table 2) had a total of 257 tests sent, with a median of 2 tests per patient (Q1–Q3 1–4, range 1–12 tests). Fluorescence in situ hybridization (FISH) testing had the shortest turnaround time, and WES/WGS had the longest. The highest rates of variants of unknown significance were seen in gene panels, mitochondrial gene sequencing, and WES/WGS tests. The age at test result generally increased with advancing test complexity or specialization (Table 2). At least one biochemical test (e.g., plasma amino acids, urine organic acids) was sent for 41 patients. The most common single gene tested was CHD7 (four patients). Clinical WES/WGS was performed for seven patients and resulted in a molecular genetic diagnosis in three (43%). 10/87 (11%) patients who had a genetics or metabolism consultation at our institution did not have testing for a genetic or metabolic disorder sent, and 19/96 (20%) of patients who had a test sent for a genetic or metabolic disorder did not have a genetics or metabolism consultation at our hospital.

Genetic diagnosis

Forty-seven (28%) of the 170 deceased patients had a laboratory-confirmed genetic diagnosis made, with 40 (24%) diagnosed after birth. Twenty-two of 40 (55%) postnatal diagnoses were made within the first 6 months of life, and 14/40 (35%) postnatal diagnoses (14/47 (30%) overall diagnoses) were made postmortem (Figure 2). The diagnoses and testing modalities leading to diagnosis are detailed in Supplementary Table 1 online. Sixteen of 40 (40%) patients with laboratory-confirmed postnatal diagnoses had clinical diagnoses made prior to the laboratory confirmation, although this information was not available for two patients with trisomy 21 diagnosed before transfer to our institution. Two diagnoses involved a VUS found in combination with a likely pathogenic or pathogenic variant in a gene associated with an autosomal recessive disorder, and three additional diagnoses also involved two variants thought to cause an autosomal recessive disorder without confirmation of phase documented in the medical record. If these five patients are not considered as having molecular genetic diagnoses, the overall diagnostic yield drops to 42/170 (25%), with 35/170 (21%) diagnosed after birth, 20/35 (57%) diagnoses made within the first 6 months of life, and 12/35 (34%) diagnosed postmortem.

Ten of 47 diagnosed patients (21%) had a chromosomal aneuploidy syndrome, with trisomy 21 accounting for 5/10 (50%). Single-gene testing (sequencing or targeted mutation analysis) was the most common genetic-testing modality leading to postnatal diagnosis (13/40, 33%), followed by chromosomal microarray (8/40, 20%), deletion/duplication analysis (5/40, 13%), and FISH or karyotype (5/40, 13%).

**Table 1** Characteristics of infants admitted to the NICU who later died.

| Diagnosis                                      | N (%) |
|------------------------------------------------|-------|
| Multiple congenital anomalies                  | 27/170 (16) |
| Acquired gastrointestinal disease              | 20/170 (12) |
| Perinatal depression/birth asphyxia            | 17/170 (10) |
| Congenital heart defect                        | 21/170 (12) |
| Prematurity                                    | 12/170 (7)  |
| Neurologic disorder                            | 10/170 (6)  |
| Metabolic disorder                             | 8/170 (5)   |
| Renal disorder                                 | 9/170 (5)   |
| Pulmonary hypertension                         | 8/170 (5)   |
| Acquired respiratory disorder                  | 6/170 (4)   |
| Gastrointestinal malformation                  | 7/170 (4)   |
| Genetic syndrome                               | 5/170 (3)   |
| Infection                                      | 5/170 (3)   |
| Congenital hematologic/oncologic disorder       | 5/170 (3)   |
| Other congenital disorders<sup>a</sup>          | 5/170 (3)   |
| Apparent life-threatening event or arrest at home | 3/170 (2)   |

**Table 2** Total NICU days and age at death.

| Total NICU days                                         | Median (Q1–Q3) | Minimum, maximum |
|---------------------------------------------------------|----------------|-----------------|
| Median (Q1–Q3)                                          | 9.0 (2.0–28.0) | 0.0, 261.0      |

| Age at death, days                                      | Median (Q1–Q3) | Minimum, maximum |
|---------------------------------------------------------|----------------|-----------------|
| Median (Q1–Q3)                                          | 48.0 (12.8–168.0) | 0.0, 1660.0    |

| Location of Death                                      | N (%)          |
|--------------------------------------------------------|----------------|
| Home                                                   | 13/170 (8)     |
| NICU                                                   | 101/170 (59)   |
| Other unit/floor in the hospital                       | 41/170 (24)    |
| Other<sup>b</sup>/unknown                              | 15/170 (9)     |

NICU, neonatal intensive care unit.

<sup>a</sup>Congenital airway/pulmonary disorder (2), congenital dermatologic disorder (2), vein of Galen malformation (1).

<sup>b</sup>En route to the hospital or at an outside hospital.
median age at laboratory-confirmed genetic diagnosis (excluding prenatal and postmortem diagnoses) was 46.5 days (Q1–Q3 14.0–108.0 days, range 4.0–602.0 days). Three diagnoses were cancer-related: two patients had leukemia with MLL gene rearrangements and one had trisomy 21–associated transient myeloproliferative disorder with a pathogenic variant in GATA1.

Of the patients who had a laboratory-confirmed genetic diagnosis made prior to death, 31/33 (94%) had care redirected and 23/27 (85%) had life support withdrawn (this information was not available for all patients). This was not significantly different from the figures for those who did not have a laboratory-confirmed genetic diagnosis made prior to death (106/131 (81%), p = 0.11; 93/126 (74%), p = 0.32).

Characteristics of patients who underwent an evaluation for a genetic or metabolic disorder

The proportion of patients who had an evaluation for a genetic or metabolic disorder varied by cause of death (Figure 1). A subgroup of 49 patients who died from acquired gastrointestinal disease, prematurity, hypoxic ischemic encephalopathy, or intracranial hemorrhage had lower rates of genetics or metabolism consultation (10/49, 20%) or testing for a genetic or metabolic disorder (10/49, 20%). For the remainder of the patients (excluding those for whom information was not available on the cause of death), 60/99 (61%) had a genetics or metabolism consultation and 70/99 (71%) had testing for a genetic or metabolic disorder. These differences were statistically significant (p < 0.001).

A smaller proportion of infants who had a genetics or metabolism consultation were preterm than of those who did not have a consultation (35/87 (40%) vs. 59/83 (71%); p < 0.001). The median age on NICU admission was similar (8.0 (Q1–Q3 2.0–30.0) vs. 7.0 (Q1–Q3 1.0–32.0) days; p = 0.69), although the median age at death was significantly higher (92.0 (Q1–Q3 32.0–285.0) vs. 20.0 (Q1–Q3 7.0–100.0) days; p < 0.001) and total number of days in the NICU was significantly longer (16.0 (Q1–Q3 3.0–49.0) vs. 5.0 (Q1–Q3 1.0–14.0) days; p < 0.001) for infants who had a genetics or metabolism consultation. The proportion who had care redirected (73/82 (89%) vs. 64/82 (78%); p = 0.09) or life support removed (57/73 (78%) vs. 59/80 (74%); p = 0.58) was similar in the two groups. These findings were again seen when comparing the 106/170 (62%) patients who had either a genetics or metabolism consultation or a test for a genetic or metabolic condition to those who had neither (Table 3).

DISCUSSION

We present the first comprehensive analysis of the diagnostic odyssey for infants in a level IV NICU that focuses on a population at high risk for genetic disease: those who do not survive early childhood. Our data show that while an evaluation for a genetic or metabolic disorder was pursued in over half of these infants, a molecular diagnosis was confirmed in only 28%, and 30% of these diagnoses were made postmortem. This suggests that a number of infants may stand to benefit from a laboratory-confirmed genetic diagnosis but that this opportunity for diagnosis before death is missed, owing to the nature of the traditional diagnostic genetic evaluation. Previous estimates of the contribution of genetic disorders to mortality in the NICU have ranged from 5% to 50% depending on the definition of “genetic disorder” and whether or not congenital anomalies, which are estimated to produce 30% of the infant mortality rate,11 are included.1–5,12 Indeed, the true burden of genetic disease in the neonatal population is difficult to ascertain as these data were generally obtained before the widespread use of next-generation sequencing. This may result in an underestimate of
Table 2 Usage, turnaround time, age at test result, and yield of diagnostic genetic testing.

| Genetic test                                      | Patients | Tests | Turnaround time, b days | Age at test result, days | Result c, N (%) | Median (Q1–Q3), N |
|--------------------------------------------------|----------|-------|--------------------------|--------------------------|-----------------|-------------------|
| Karyotype                                       | 30       | 30    | 5.0                      | 10.0                     | Positive: 6/30 (20) | (4.0–10.5), 9, 6.0–21.3, 20 |
| Fluorescence in situ hybridization               | 8        | 9     | 3.0                      | 10.0                     | Positive: 2/9 (22)   | (min–max 1.0–8.0), 3, 5.3–227.8, 4 |
| Chromosomal microarray                           | 48       | 51    | 16.5                     | 35.0                     | Positive: 8/51 (16) | (10.0–23.0), 40, 16.5–66.5, 41 |
| Single-gene testing (sequencing or targeted       | 47       | 94    | 22.0                     | 82.0                     | Positive: 12/94 (13) | (13.0–34.0), 87, 41.0–182.5, 89 |
| mutation analysis)                               |          |       |                          |                          |                 |                   |
| Deletion/duplication analysis                    | 22       | 27    | 21.0                     | 73.0                     | Positive: 5/27 (19) | (14.0–41.0), 27, 40.0–139.0, 27 |
| Methylation analysis                             | 5        | 5     | 8.0                      | 69.0                     | Positive: 0/5 (0)   | (6.0–24.0), 5, 11.0–179.0, 5 |
| Triplet repeat study                             | 2        | 2     | 42.0                     | 82.0                     | Positive: 0/2 (0)    | (N/A), 1, min–max 77.0–87.0, 2 |
| Gene panel                                       | 20       | 25    | 48.0                     | 106.0                    | Positive: 4/25 (16) | (32.0–56.0), 23, 54.0–231.0, 23 |
| Mitochondrial gene testing                        | 5        | 7     | 81.0                     | 147.0                    | Positive: 1/7 (14)   | (61.0–157.0), 7, 74.0–446.0, 7 |
| Whole-exome or whole-genome sequencing           | 7        | 7     | 161.0                    | 456.0                    | Positive: 3/7 (43)   | (114.0–268.0), 7, 170.0–602.0, 7 |

VUS, variant of uncertain significance.

*Number of patients who had the test sent (patients may have had more than one test sent). **Turnaround time** refers to the number of days between the date the specimen was received by the lab and the date of the result report. This information was not available for all tests reviewed. ***Positive*** includes pathogenic or likely pathogenic variant; **Negative** includes benign/likely benign variant; **None** indicates that there was no result from the test or the test result was unknown. A single pathogenic variant in a gene associated with an autosomal recessive condition (i.e., CFTR) was not considered a positive result. Test could have more than one category of result (e.g., one pathogenic variant and one VUS). *This patient had a “positive” result on genetic testing but was not determined to have a molecular genetic diagnosis made (it was unclear whether the variant identified was responsible for the patient’s presentation). One patient had whole-genome sequencing with a turnaround time of 294 days and a positive result.
the contribution of Mendelian disorders to neonatal mortality. Conversely, the inclusion in these studies of all infants with congenital malformations, some of which may be related to environmental or teratogenic factors, may overestimate the presumed genetic contributions. Our data also reflect that genetic disorders and congenital anomalies contribute greatly to mortality in the infant and early childhood period, although our study is unique in identifying how many undergo a diagnostic genetic evaluation.

We have shown that while these high-risk neonates embark on their genetic diagnostic odyssey within the first week of life, the turnaround time for most genetic tests, consistent with prior data, is typically in the order of several weeks to months. The diagnostic odyssey can therefore last for months (or years) owing to the usual stepwise structure of the traditional genetic diagnostic evaluation, where subsequent rounds of testing are sent only after prior testing has been unrevealing. This is reflected in the later median age found in results of tests such as gene panels and mitochondrial gene sequencing, compared to cytogenetic studies such as karyotype and FISH, which are often sent in the first round of genetic testing. As a chromosomal microarray is recommended as the first-tier diagnostic test for patients with multiple congenital anomalies, affected many patients in our study, it is not surprising that this and single-gene testing were the most commonly utilized genetic tests in our study. A previous study had also found high rates of chromosomal microarray use in a NICU population, but that single-gene testing was sent in a minority. WES or WGS has historically only been performed after all previous testing has returned negative, which is reflected in the extremely low rate of usage that we found. WES has previously been shown to have

---

**Figure 2 Timing of the molecular genetic diagnosis.** *Two postnatal (birth to 6 months), one postnatal (6 months to 2 years), and two postmortem diagnoses involve two variants thought to cause an autosomal recessive disorder, without confirmation of phase documented in the medical record. Two of these diagnoses (one postnatal and one postmortem) also involve a variant of uncertain significance found in combination with a likely pathogenic or pathogenic variant. FISH, fluorescence in situ hybridization.

**Table 3** Comparison of infants who did and did not undergo a genetic diagnostic evaluation.

|                        | Genetics/metabolism consult or test (n = 106) | No genetics/metabolism consult or test (n = 64) | \( p \) |
|------------------------|---------------------------------------------|-------------------------------------------------|------|
| Age at NICU admission, days | 8.0 (2.0–34.3) | 7.0 (0.0–25.5) | 0.16 |
| Total time in the NICU, days | 13.5 (3.0–35.3) | 5.0 (1.0–15.3) | 0.003 |
| Age at death, days | 92.0 (27.8–251.3) | 17.5 (7.0–64.5) | <0.001 |

\( \text{N/total (\%)} \)

|                        | \( n/\text{total (\%)} \) |
|------------------------|----------------------------|
| Preterm               | \( 46/106 (43) \) | \( 48/64 (75) \) | <0.001 |
| Care redirected\( ^a \) | \( 87/101 (86) \) | \( 50/63 (79) \) | 0.28 |
| Life support removed\( ^b \) | \( 68/91 (75) \) | \( 48/62 (77) \) | 0.85 |

\( ^a \text{Information not available for 6 patients.} \quad ^b \text{Information not available for 17 patients.} \)
a diagnostic yield of approximately 25–30%,23,24 although this yield may be higher in the neonatal period, particularly in a sequencing-naïve population.14–18,24,25 The diagnostic yield for the testing modalities examined in our study ranged from 13–43% (excluding studies for which there were no positive results) and was highest for WES/WGS, although the median turnaround time was between 5 and 6 months. Interestingly, we found that most postnatal diagnoses in our study were made by single-gene testing, while a prior study of genetic evaluations in the NICU had found that most genetic diagnoses were of chromosomal aneuploidy syndromes, particularly trisomy 21, which may be due to their population of primarily living patients.19 This may also reflect the complexity of patients admitted to our NICU for diagnostic evaluation and suggests that the early addition of large, next-generation sequencing panels, or WES, to the NICU genetic evaluation may increase the diagnostic yield, as is reflected in a recent study demonstrating a diagnostic yield of 36.7% for WES in a NICU setting, with 54.9% of diagnosed infants having WES as a first-tier approach,18 and in a 40% diagnostic yield found in a NICU population using a large panel of disease genes.26 As sequencing technologies continue to improve and the cost decreases, the use of WES and other massively parallel sequencing technologies will probably expand, although given the high rate of chromosomal diagnoses found in the NICU population, it may not serve well as an independent testing modality.19,27 Furthermore, the use of broader sequencing panels and WES also increases the potential to find VUS, as is reflected in our data.

Our data further demonstrate that there are two patient populations who are admitted to our NICU and later die: those who die from causes that are less likely to be related to genetic disorders, such as perinatal asphyxia or complications of prematurity, and those with unusual presentations who undergo diagnostic genetic evaluation. Our results suggest that infants with suspected genetic disorders spend more time in the NICU prior to death, providing an opportunity for genetic diagnosis, particularly as we have shown that deaths in our study most often occur after redirection of care or withdrawal of life support and are therefore anticipated deaths, consistent with prior literature on deaths in the NICU11,13,20 (although not all deaths in our study occurred in the hospital setting). Previous research has demonstrated that NICU resources are preferentially directed toward infants who will survive to discharge, as these infants traditionally account for the majority of NICU bed days,28 which argues that NICU expenditures are less likely to be for “futile” care. Infants with suspected genetic disorders, particularly at a level IV referral center such as ours, may potentially increase expenses for such “futile” care. Owing to the high cost of NICU admissions, billed to insurance for thousands of dollars per day,28 the ability to find a diagnosis earlier may result in substantial cost savings if it allows for curative treatments or aids in the decision to redirect care earlier with diagnoses for which the prognosis is poor. It has previously been suggested that early genetic diagnosis may increase mortality in the neonatal period but decrease infant mortality due to this phenomenon.29 It is difficult to quantify the impact of a genetic diagnosis, particularly retrospectively, but providing closure to parents at the end of an infant’s life is an invaluable benefit.

In addition to providing guidance and closure at the end of life, finding a genetic diagnosis has also been shown to alter clinical management18,25,26,30–33 or aid in the decision to consult palliative care in the NICU.16,19 While genetic testing is expensive, particularly WES and WGS, these tests may in the end be cost-saving, particularly given the duration and cost of the traditional genetic diagnostic evaluation.13,30,33 Identifying the genetic cause of a patient’s condition puts an end to the diagnostic odyssey, obviating the need for further costly testing. In addition, having a diagnosis can help the families and caregivers of critically ill infants to access resources particular to their child and to prepare for the future, even if the diagnosis is life-limiting; it can also allow families to bond together in rare disease communities.34,35 Finally, a laboratory-confirmed diagnosis allows for testing of other at-risk family members25 and for the provision of reproductive counseling,26 which holds great value for parents36 and is of particular importance in the NICU, where parents faced with the loss of their first child are often looking for guidance with their next pregnancy. It is difficult to speculate how parents and the care team in our cohort would have used information gained from a molecular diagnosis in terms of earlier redirection of care. As for management changes, there were treatable conditions in our diagnosed cohort such as ornithine transcarbamylase deficiency, which was recognized and appropriately treated as a urea cycle disorder with confirmation provided by the genetic testing. We do suspect, however, that there were missed opportunities for management changes owing to the lack of a molecular genetic diagnosis, and further research is warranted in this area, as well as to better identify which patients in the NICU stand to benefit the most from a genetics or metabolism consultation and are potentially being overlooked at present.

Limitations of this study include the small sample size and retrospective design. We recognize that the proportion of infants with suspected genetic disease is enriched in our study population owing to the nature of our level IV NICU. This enrichment enabled us to evaluate a larger number of patients in order to be able to more accurately reflect characteristics such as the turnaround time of genetic testing, at the expense of generalizability of these mortality statistics to the newborn population as a whole. Our study was limited to review of medical records, which may not always be updated to reflect a patient’s death outside our hospital. Therefore, deaths may have occurred of which we were not aware, although we suspect this would cover only a minority of patients. Furthermore, as our NICU is a referral center with a high volume of transfers and retro-transfers, it is difficult to capture an infant’s entire diagnostic odyssey, particularly if it began at another institution. Tests such as FISH and karyotype are particularly likely to have been performed...
Diagnosis of genetic disorders and infant mortality | WOJCK et al

elsewhere, judging by the smaller amount of data we had regarding these modalities. However, our study is valuable in reflecting current practices at a high-volume newborn referral center that cares for many infants with rare and likely genetic disease. Confirmed genetic diagnoses may also be difficult to extract from the medical record, particularly as documentation and follow-up may be incomplete after a child’s death. Indeed, one patient had a likely pathogenic variant found postmortem, although it took an additional 3 years before the pathogenicity was fully established based on functional studies. This further highlights the complexity of the diagnostic odyssey for this unique patient population.

We have shown that over half of infants admitted to the NICU who do not survive early childhood are suspected to have a genetic disorder and that these patients represent a unique population in the NICU who would probably benefit from a laboratory-confirmed genetic diagnosis. The current tiered approach to genetic testing results in a delayed diagnosis and has a relatively low diagnostic yield. While the median time to genetic diagnosis in our study was 46.5 days, for those who remained undiagnosed at death, the diagnostic odyssey may still continue. Families who continue to pursue diagnosis after the death of a child face even greater barriers, as functional data to investigate candidate genes and variants are difficult to obtain and insurance does not cover postmortem testing. Further research is needed to determine the best approach to genetic diagnosis in the NICU in order to improve the care that we provide to infants and their families.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at http://www.nature.com/gim

ACKNOWLEDGMENTS

M.H.W. is supported by NIH 4 T32 HD 7466-20. P.B.A. is supported by NIH/NIAIM 1R01AR068429-01 and NICHD/NHGRI/NIH U19HD077671. We thank the patients that we care for at our hospital and their families, which continue to teach and enrich us all. We are also very grateful to Henry Feldman for statistical consultation.

DISCLOSURE

M.C.T. is currently employed by Ambry Genetics. The other authors declare no conflict of interest.

REFERENCES

1. Simpson CD, Ye XY, Hellmann J & Tomlinson C. Trends in cause-specific mortality at a Canadian outborn NICU. Pediatrics 2010;126:1538.
2. Hudomte SM, Kirby RS, Senner JW & Cunniff C. Contribution of genetic disorders to neonatal mortality in a regional intensive care setting. Am J Perinatol 1994;11:100–103.
3. Weiner J, Sharma J, Lantos J & Kilbride H. How infants die in the neonatal intensive care unit: trends from 1999 through 2008. Arch Pediatr Adolesc Med 2011;165:630–634.
4. Sankaran K, Chien LY, Walker R, Seshia M & Ohlsson A. Canadian Neonatal Network. Variations in mortality rates among Canadian neonatal intensive care units. CMAJ 2002;166:173–178.
5. Jacob J, Kamitsuka M, Clark RH, Kelleher AS & Spitzer AR. Etiologies of NICU deaths. Pediatrics 2015;135:59.
6. Yoon PW, Olney RS, Khoury MJ, Sappenfield WM, Chavez GF & Taylor D. Contribution of birth defects and genetic diseases to pediatric hospitalizations. A population-based study. Arch Pediatr Adolesc Med 1997;151:1096–1103.
7. Stevenson DA & Carey JC. Contribution of malformations and genetic disorders to mortality in a children’s hospital. Am J Med Genet A 2004;126A:393–397.
8. Meng M & Zhang YP. Impact of inborn errors of metabolism on admission in a neonatal intensive care unit: a 4-year report. J Pediatr Endocrinol Metab 2013;26:689–693.
9. Nelson K & Holmes LB. Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 1989;320:19–23.
10. Matthews TJ & Driscoll AK. Trends in Infant Mortality in the United States, 2005–2014. NCHS data brief, no 279. Hyattsville, MD: National Center for Health Statistics. 2017.
11. Wen SW, Liu S, Joseph KS, Rouleau J & Allen A. Patterns of infant mortality caused by major congenital anomalies. Teratology 2000;61:342–346.
12. Costa S, Rodrigues M, Centeno MJ, et al. Diagnosis and cause of death in a neonatal intensive care unit—how important is autopsy? J Matern Fetal Neonatal Med 2011;24:760–763.
13. Shashi V, McConkie-Rosell A, Rosell B, et al. The utility of the traditional medical genetic diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med 2014;16:176–182.
14. Smith LD, Willig LK & Kingsmore SF. Whole-exome sequencing and whole-genome sequencing in critically ill neonates suspected to have single-gene disorders. Cold Spring Harb Perspect Med 2015;6:a023168.
15. Saunders CJ, Miller NA, Soden SE, et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci Transl Med 2012;4:154ra135.
16. Willig LK, Petrikin JE, Smith LD, et al. Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings. Lancet Respir Med 2015;3:377–387.
17. Soden SE, Saunders CJ, Willig LK, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med 2014;6:265ra168.
18. Meng L, Pammi M, Saronvala A, et al. Use of exome sequencing for infants in intensive care units: ascertainment of severe single-gene disorders and effect on medical management. JAMA Pediatr 2017;17:e173438.
19. Malam F, Hartley T, Gillespie MK, et al. Benchmarking outcomes in the Neonatal Intensive Care Unit: cytogentic and molecular diagnostic rates in a retrospective cohort. Am J Med Genet A 2017;173:1839–1947.
20. Berger TM & Hofer A. Causes and circumstances of neonatal deaths in 108 consecutive cases over a 10-year period at the Children’s Hospital of Lucerne, Switzerland. Neonatology 2009;95:157–163.
21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N & Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.
22. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmentanl disorders or congenital anomalies. Am J Hum Genet 2010;86:749–764.
23. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 2013;369:1502–1511.
24. Farwell KD, Shahmirzadi L, El-Khechen D, et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unsselected families with undiagnosed genetic conditions. Genet Med 2015;17:578–586.
25. Stark Z, Tan TY, Chong B, et al. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genet Med 2016;18:1090–1096.
26. Daoud H, Luco SM, Li R, et al. Next-generation sequencing for diagnosis of rare diseases in the neonatal intensive care unit. CMAJ 2016;188:254.
27. Xue Y, Ankala A, Wilcox WR & Hegde MR. Solving the molecular diagnostic odyssey conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/gene sequencing. Genet Med 2015;17:444–451.
28. Meadow W, Cohen-Cutler S, Spekle B, et al. The prediction and cost of futility in the NICU. Acta Paediatr 2012;101:397–402.

ORIGINAL RESEARCH ARTICLE
29. Petrikin JE, Willig LK, Smith LD & Kingsmore SF. Rapid whole genome sequencing and precision neonatology. *Semin Perinatol* 2015;39:623–631.

30. Tan TY, Dillon OJ, Stark Z, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. *JAMA Pediatr* 2017;171:855–86.

31. Riggs ER, Wain KE, Riethmaier D, et al. Chromosomal microarray impacts clinical management. *Clin Genet* 2014;85:147–153.

32. Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. *Genet Med* 2011;13:770–776.

33. Stark Z, Schofield D, Alam K, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. *Genet Med* 2017;19:867–874.

34. Knott M, Leonard H & Downs J. Genetic drift. The diagnostic odyssey to Rett syndrome: the experience of an Australian family. *Am J Med Genet A* 2012;158A:10–12.

35. Carmichael N, Tsipis J, Windmueller G, Mandel L & Estrella E. “Is it going to hurt?”: the impact of the diagnostic odyssey on children and their families. *J Genet Couns* 2015;24:325–335.

36. Might M & Might CC. What happens when N=1 and you want plus 1?. *Prenat Diagn* 2017;37:70–72.

37. Pozzi S, Tan WH & Martinez-Barbera J. Characterization of a novel HESX1 mutation in a pediatric case of septo-optic dysplasia. *Clin Case Rep* 2017;5:463–470.